Abstract: The present invention provides a factor capable of predicting an effect of a medicinal therapy on a cancer such as HER2 positive cancer. More specifically, the present invention provides a method of predicting the effect of the medicinal therapy on the cancer, comprising: (1) analyzing a methylation level of a cytosine residue in one or more CpG sites present within a nucleotide sequence in a promotor region, an untranslated region or a translated region of HSD17B4 gene in a sample taken from a human subject; and (2) predicting the effect of the medicinal therapy on the cancer based on the analyzed methylation level.
Type:
Grant
Filed:
March 15, 2017
Date of Patent:
January 4, 2022
Assignees:
NATIONAL CANCER CENTER, H.U. Group Research Institute G.K.
Abstract: The present invention provides novel Epstein Barr virus (EBV) variants including those associated with increased risk for developing nasopharyngeal carcinoma (NPC).
Abstract: The invention relates to a non-invasive, simple, inexpensive, quick method to assess embryo competence in vitro by detecting nucleic acid-containing extracellular vesicles in the culture medium of the embryo. The culture medium may be fixed before being stained with propidium iodide and analysed by flow cytometry.
Type:
Grant
Filed:
November 25, 2016
Date of Patent:
November 9, 2021
Assignees:
Pécsi Tudományegyetem, Semmelweis Egyetem
Inventors:
Éva Pállinger, Júlia Szekeres, Zoltán Bognár, Krisztina Gödöny, József Bódis, Edit Buzás
Abstract: The present invention is based on BCR-ABL1 splice variants which result from insertion and/or truncation of the bcr-abl1 transcript and the finding that these variants provide resistance to kinase domain inhibitors such as imatinib, nilotinib and dasatinib.
Abstract: The invention includes methods and apparatus for separating mutations, especially rare and unknown mutations, using heteroduplex binding proteins. Nucleic acids may optionally be nicked at or near the mutation in order to promote heteroduplex binding protein recognition and binding. In particular, using the disclosed methods, it is possible to separate heteroduplexed nucleic acid strand pair from homoduplexed nucleic acid strand pairs having similar sequences and being at a much higher concentration. Once the heteroduplexed nucleic acids are isolated and recovered, it is straightforward to analyze the sequences of the heteroduplexed nucleic acids, e.g., using sequencing or hybrid assays.
Type:
Grant
Filed:
May 19, 2016
Date of Patent:
September 28, 2021
Assignee:
Quantum-Si Incorporated
Inventors:
Andrea Marziali, Milenko Despotovic, Matthew Wiggin, Joel Pel
Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of PLA2G16, CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
Abstract: The present application relates to multiplex detection of nucleic acid molecules. In particular, the present application provides a method for detecting target nucleic acid sequences, said method can simultaneously detect the presence of multiple target nucleic acid sequences in a sample. In addition, the present application further provides a probe set, and a kit comprising one or more said probe sets, said probe set and said kit can be used to carry out the method of the invention.
Abstract: This disclosure is in the field of molecular biology and medical diagnosis and provides means and methods for determining the prognosis and disease outcome of a subject having a melanoma. More in particular, this disclosure provides a method for determining whether a subject having a melanoma has a poor prognosis, the method comprising the step of determining in a sample from the subject whether the LY75 promoter is methylated and if the LY75 promoter is methylated, classifying the subject as having a poor prognosis.
Abstract: Genetic markers are described for discriminating or detecting viruses causing infectious aquatic organism diseases, and a method of discriminating and detecting the viruses using the same is disclosed, in which the method includes selecting and amplifying a DNA nucleotide sequence encoding a gene specific for viral hemorrhagic septicemia virus (VHSV), red sea bream iridovirus (RSIV) or infectious spleen and kidney necrosis virus (ISKNV), which is a virus causing red sea bream iridovirus disease, or Koi herpesvirus (KHV); hybridizing a peptide nucleic acid (PNA) that specifically recognizes the amplification product; controlling the temperature of the hybridization product to obtain a temperature-dependent melting curve; and discriminating the viral type or detecting whether or not fish are infected with the viral type by analyzing the obtained melting curve to determine a melting temperature.
Type:
Grant
Filed:
October 20, 2019
Date of Patent:
June 22, 2021
Assignee:
NATIONAL INSTITUTE OF FISHERIES SCIENCE
Inventors:
Miyoung Cho, Myoung Ae Park, Bo-Young Jee, Seong Don Hwang
Abstract: Genetic markers are described for discriminating or detecting viruses causing infectious aquatic organism diseases, and a method of discriminating and detecting the viruses using the same is disclosed, in which the method includes selecting and amplifying a DNA nucleotide sequence encoding a gene specific for viral hemorrhagic septicemia virus (VHSV), red sea bream iridovirus (RSIV) or infectious spleen and kidney necrosis virus (ISKNV), which is a virus causing red sea bream iridovirus disease, or Koi herpesvirus (KHV); hybridizing a peptide nucleic acid (PNA) that specifically recognizes the amplification product; controlling the temperature of the hybridization product to obtain a temperature-dependent melting curve; and discriminating the viral type or detecting whether or not fish are infected with the viral type by analyzing the obtained melting curve to determine a melting temperature.
Type:
Grant
Filed:
October 20, 2019
Date of Patent:
June 22, 2021
Assignee:
NATIONAL INSTITUTE OF FISHERIES SCIENCE
Inventors:
Miyoung Cho, Myoung Ae Park, Bo-Young Jee, Seong Don Hwang
Abstract: Genetic markers are described for discriminating or detecting viruses causing infectious aquatic organism diseases, and a method of discriminating and detecting the viruses using the same is disclosed, in which the method includes selecting and amplifying a DNA nucleotide sequence encoding a gene specific for viral hemorrhagic septicemia virus (VHSV), red sea bream iridovirus (RSIV) or infectious spleen and kidney necrosis virus (ISKNV), which is a virus causing red sea bream iridovirus disease, or Koi herpesvirus (KHV); hybridizing a peptide nucleic acid (PNA) that specifically recognizes the amplification product; controlling the temperature of the hybridization product to obtain a temperature-dependent melting curve; and discriminating the viral type or detecting whether or not fish are infected with the viral type by analyzing the obtained melting curve to determine a melting temperature.
Type:
Grant
Filed:
October 20, 2019
Date of Patent:
June 22, 2021
Assignee:
NATIONAL INSTITUTE OF FISHERIES SCIENCE
Inventors:
Miyoung Cho, Myoung Ae Park, Bo-Young Jee, Seong Don Hwang
Abstract: The present invention relates to the fields of medicine and molecular diagnostics. In particular, it relates to a novel method for the treatment, prevention and/or delay of cancer and to a diagnostic method involving detection of a novel auto-active and intracellular mutant of MET.
Type:
Grant
Filed:
November 18, 2015
Date of Patent:
June 15, 2021
Inventors:
Anna Catharina Navis, Wilhelmus Petrus Johannes Leenders, Thomas Würdinger
Abstract: Biomarkers useful for the diagnosis and treatment of acute ischemic stroke are disclosed. Also provided is a quantitative assay method for accurately identifying transcript number in a biological sample.
Type:
Grant
Filed:
October 14, 2014
Date of Patent:
June 1, 2021
Assignee:
THE RESEARCH FOUNDATION FOR STATE UNIVERSITY OF NEWYORK
Abstract: The invention is directed to methods, kits, and compositions, for amplifying and detecting Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) in a sample, which comprises a variety of combinations of forward oligonucleotide primers, reverse oligonucleotide primers, and oligonucleotide probes.
Abstract: Methods and compositions for diagnosing the presence of a cancer cell in an individual are provided. Methods and compositions for identifying a tumor-specific signature in an individual having cancer are also provided. Methods and compositions for diagnosing the presence of an infectious agent in an individual and/or for identifying an infectious agent-specific signature in an infected individual are provided. Methods and compositions for diagnosing the presence of a disease in an individual are also provided. Methods and compositions for identifying a disease-specific signature in an individual having the disease are also provided.
Type:
Grant
Filed:
June 8, 2017
Date of Patent:
May 11, 2021
Assignee:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Abstract: A retrotransposable element based multiplexed qPCR assay to robustly quantitate and distinguish cell free DNA integrity and concentration in blood plasma and serum is described. The multiplexed system for characterizing cancer in humans includes a sample of serum, plasma, urine, or other biological fluid, the sample comprising cell free DNA, the cell free DNA comprising long and short retrotransposable element targets and an added internal positive control, the long and short targets being independent of each other, a distinctly labeled TaqMan probe corresponding to each target, a forward primer and a reverse primer corresponding to each target, a DNA standard for generating standard curves, a qPCR system for amplifying the targets and a qPCR data analysis system.
Abstract: The invention provides a Siniperca chuatsi IL-6 gene and a detection method for a disease-resistant SNP marker. A cDNA sequence of S. chuatsi IL-6 gene is cloned, as shown in SEQ ID NO: 1. AIL-6 gene gDNA sequence containing an intron of the S. chuatsi IL-6 gene is cloned, as shown in SEQ ID NO: 2. A primer for amplifying a disease-resistant SNP locus is designed according to IL-6 gDNA sequence, and S. chuatsi IL-6 gene is amplified to obtain an amplification product which is sequenced, and the SNPs loci relevant to virus disease-resistance are found out and the SNP locus is determined according to DNA peak profile. The IL-6 cDNA full-length sequence and IL-6 gDNA full-length sequence are cloned firstly. The SNP locus relevant to virus disease resistance of S. chuatsi IL-6 gene is detected, thereby providing a new method for breeding of S. chuatsi.
Type:
Grant
Filed:
July 8, 2019
Date of Patent:
April 27, 2021
Assignee:
SOOCHOW UNIVERSITY
Inventors:
Hezhong Huang, Yao Lu, Ruiming Jin, Ze Li
Abstract: The invention relates to a porous planar cell capture system for use in determining the presence and/or amount of cells, for example, viable cells, in a liquid sample, and to methods of using such a cell capture system. The cell capture system contains a fluid permeable, planar membrane adopted to retain cells thereon, a fluid permeable support member that supports the membrane, and an optional register associated with the membrane.
Type:
Grant
Filed:
February 25, 2019
Date of Patent:
April 13, 2021
Assignees:
Charles River Laboratories, Inc., ReaMetrix Inc.
Inventors:
Norman R. Wainwright, Bala S. Manian, Eric Stimpson, Brian J. Kolonia, Robert K. Kolonia
Abstract: The invention provides methods for detecting a cellular proliferative disorder (e.g., urothelial cancer) in a subject by assessing the methylation status of the GULP1 promoter in a nucleic acid sample. The methods of the invention are useful for diagnostic, prognostic as well as therapeutic regimen predictions.
Type:
Grant
Filed:
March 17, 2016
Date of Patent:
March 9, 2021
Assignee:
The Johns Hopkins University
Inventors:
Masamichi Hayashi, Elisa Guida, Mohammad Hoque
Abstract: Methods and compositions for diagnosing the presence of a cancer cell in an individual are provided. Methods and compositions for identifying a tumor-specific signature in an individual having cancer are also provided. Methods and compositions for diagnosing the presence of an infectious agent in an individual and/or for identifying an infectious agent-specific signature in an infected individual are provided. Methods and compositions for diagnosing the presence of a disease in an individual are also provided. Methods and compositions for identifying a disease-specific signature in an individual having the disease are also provided.
Type:
Grant
Filed:
December 29, 2015
Date of Patent:
March 2, 2021
Assignee:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE